Drugs / ARD-501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06126653 | Aug 2024 → Jan 2025 | autism spectrum disorder | Aardvark Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARD-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06126653 ↗ |
| Route | Oral | “taken orally” NCT06126653 ↗ |